Literature DB >> 29282998

Clinical significance of neuregulin 4 (NRG4) in gestational diabetes mellitus.

Meryem Kurek Eken1, Cigdem Yayla Abide2, Gulcin Sahin Ersoy3, Tugba Altun Ensari4, Oya Pekin5, Ozge Cevik6.   

Abstract

OBJECTIVE: Gestational diabetes mellitus (GDM) is defined as glucose intolerance detected during pregnancy. GDM is increasing worldwide and is associated with adverse maternal and fetal outcomes. Neuregulin 4 (NGR4) is epidermal growth factor like signaling molecule. It plays an important role in cell to cell communication furthermore recent studies indicate that NRG4 may work as a novel adipokine with a possible role in maintaining energy and metabolic homeostasis. The aim of the present study was to assess serum NRG4 levels along with several metabolic parameters in patients diagnosed with gestational diabetic mellitus.
MATERIALS AND METHODS: In this prospective cross-sectional study, the study group was composed of 63 women with GDM and 64 healthy pregnant women matched for age, body mass index (BMI) and gestational age. Blood samples were collected at the 24-28th gestational weeks. Serum NRG4, total cholesterol, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides, glucose levels during 75-gr OGTT, fasting insulin, glycosylated hemoglobin A1c (HbA1c), alanine aminotransferase (ALT) and creatinine levels were measured. Homeostasis model assessment of insulin resistance (HOMA-IR) values were calculated.
RESULTS: Serum NRG4 values were significantly elevated in the GDM group compared to the control group (p < .001). Multivariate linear regression analyzes revealed that BMI (β = 0.910, p < .001), glucose 2-h OGTT (β = 0.866, p < .001) and HOMA-IR (β = 0.222, p < .001) independently and positively predicted NRG4 levels.
CONCLUSIONS: Serum NRG4 levels were associated with metabolic parameters of GDM. The present study can be considered to be a guide for future studies to clarify the pathophysiology of NGR4 in GDM patients.

Entities:  

Keywords:  BMI; HOMA-IR; NRG4; gestational diabetes mellitus

Mesh:

Substances:

Year:  2017        PMID: 29282998     DOI: 10.1080/09513590.2017.1420772

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  5 in total

1.  Elevated serum neuregulin 4 levels in patients with hyperthyroidism.

Authors:  Min Li; Ying Chen; Jingjing Jiang; Yan Lu; Zhiyi Song; Shengjie Zhang; Chao Sun; Hao Ying; Xiaofang Fan; Yuping Song; Jialin Yang; Lin Zhao
Journal:  Endocr Connect       Date:  2019-06-01       Impact factor: 3.335

2.  Association between circulating neuregulin4 levels and diabetes mellitus: A meta-analysis of observational studies.

Authors:  Yao Wang; Shuai Huang; Pei Yu
Journal:  PLoS One       Date:  2019-12-09       Impact factor: 3.240

3.  Alteration of serum neuregulin 4 and neuregulin 1 in gestational diabetes mellitus.

Authors:  Lei Zhang; Bi Lu; Wenhua Wang; Shifeng Miao; Shuru Zhou; Xingbo Cheng; Jie Zhu; Changmei Liu
Journal:  Ther Adv Endocrinol Metab       Date:  2021-10-08       Impact factor: 3.565

4.  Clinical Significance of Neuregulin 4, Afamin, and SERPINB1 in Gestational Diabetes Mellitus and Their Relationship with Insulin Resistance.

Authors:  Qian Li; Chunmei Li; Jing Jin; Yang Shen; Mei Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-28       Impact factor: 2.650

5.  Serum neuregulin 4 is negatively correlated with insulin sensitivity in humans and impairs mitochondrial respiration in HepG2 cells.

Authors:  Cristina Martínez; Jèssica Latorre; Francisco Ortega; María Arnoriaga-Rodríguez; Aina Lluch; Núria Oliveras-Cañellas; Francisco Díaz-Sáez; Julian Aragonés; Marta Camps; Anna Gumà; Wifredo Ricart; José Manuel Fernández-Real; José María Moreno-Navarrete
Journal:  Front Physiol       Date:  2022-09-15       Impact factor: 4.755

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.